Data / Form D filings / Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc.: Form D filings
Perspective Therapeutics, Inc., a biotechnology company in Seattle, WA, filed 4 Form D notices with the SEC between 2018 and 2024. The latest, on March 18, 2024, reports $87.4 million sold of a $87.4 million offering to 9 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2401 Elliott Avenue, Suite 320, Seattle, WA, 98121
- Phone
- (206) 676-0900
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 728387
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 18, 2024 | New notice | $87,409,482 | $87,409,482 | 9 | Mar 4, 2024 | sec.gov | |
| Jan 22, 2024 | New notice | $20,846,671 | $20,846,671 | 1 | Jan 8, 2024 | sec.gov | |
| Feb 21, 2023 | New notice | $54,618,030 | $54,618,030 | 54 | Feb 3, 2023 | sec.gov | |
| Jul 25, 2018 | New notice | $728,750 | $728,750 | 4 | Jul 11, 2018 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Robert Williamson III | Director | |
| Frank Morich | Director | |
| Johan (Thijs) Spoor | Executive Officer, Director | |
| Lori Woods | Director | |
| Mark Austin | Executive Officer | |
| Heidi Henson | Director | |
| Jonathan Hunt | Executive Officer | |
| Markus Puhlmann | Executive Officer |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of Mar 18, 2024 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Perspective Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.